Heron Total Liab vs Short Long Term Debt Total Analysis
HRTX Stock | USD 3.44 0.03 0.86% |
Heron Therapeuti financial indicator trend analysis is much more than just examining Heron Therapeuti latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Heron Therapeuti is a good investment. Please check the relationship between Heron Therapeuti Total Liab and its Short Long Term Debt Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.
Total Liab vs Short Long Term Debt Total
Total Liab vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Heron Therapeuti Total Liab account and Short Long Term Debt Total. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Heron Therapeuti's Total Liab and Short Long Term Debt Total is 0.95. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Heron Therapeuti, assuming nothing else is changed. The correlation between historical values of Heron Therapeuti's Total Liab and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Heron Therapeuti are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Total Liab i.e., Heron Therapeuti's Total Liab and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.95 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Short Long Term Debt Total
Most indicators from Heron Therapeuti's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Heron Therapeuti current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.At this time, Heron Therapeuti's Selling General Administrative is fairly stable compared to the past year. Discontinued Operations is likely to rise to about 1.3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 28.3 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 258.2M | 227.5M | 172.6M | 181.2M | Cost Of Revenue | 46.0M | 54.9M | 65.1M | 68.4M |
Heron Therapeuti fundamental ratios Correlations
Click cells to compare fundamentals
Heron Therapeuti Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Heron Therapeuti fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 512.8M | 353.6M | 305.7M | 251.0M | 222.5M | 233.6M | |
Short Long Term Debt Total | 19.8M | 24.6M | 159.5M | 157.5M | 179.6M | 188.6M | |
Other Current Liab | 86.4M | 91.9M | 64.8M | 76.4M | 73.4M | 77.0M | |
Total Current Liabilities | 96.7M | 102.5M | 71.1M | 82.4M | 79.7M | 83.7M | |
Total Stockholder Equity | 403.8M | 236.5M | 77.6M | 13.6M | (34.0M) | (32.3M) | |
Property Plant And Equipment Net | 33.4M | 39.0M | 33.6M | 29.8M | 25.6M | 26.9M | |
Net Debt | (52.1M) | (80.5M) | 69.0M | 142.1M | 151.0M | 158.5M | |
Retained Earnings | (1.2B) | (1.4B) | (1.6B) | (1.8B) | (1.9B) | (1.8B) | |
Cash | 71.9M | 105.1M | 90.5M | 15.4M | 28.7M | 27.8M | |
Non Current Assets Total | 33.7M | 39.4M | 51.3M | 45.5M | 33.7M | 35.4M | |
Cash And Short Term Investments | 391.0M | 208.5M | 157.6M | 84.9M | 80.4M | 60.9M | |
Net Receivables | 39.9M | 41.9M | 35.5M | 52.0M | 60.1M | 63.1M | |
Common Stock Shares Outstanding | 81.8M | 90.8M | 98.5M | 108.9M | 138.1M | 145.0M | |
Liabilities And Stockholders Equity | 512.8M | 353.6M | 305.7M | 251.0M | 222.5M | 233.6M | |
Non Current Liabilities Total | 12.2M | 14.6M | 157.1M | 155.0M | 176.8M | 185.6M | |
Other Stockholder Equity | 1.6B | 1.6B | 1.7B | 1.8B | 1.9B | 2.0B | |
Total Liab | 108.9M | 117.1M | 228.1M | 237.4M | 256.5M | 269.3M | |
Property Plant And Equipment Gross | 33.4M | 39.0M | 33.6M | 29.8M | 42.6M | 44.8M | |
Total Current Assets | 479.1M | 314.2M | 254.4M | 205.4M | 188.8M | 198.2M | |
Accumulated Other Comprehensive Income | 85K | 257K | (6K) | (19K) | 13K | 13.7K | |
Short Term Debt | 7.6M | 10.1M | 2.4M | 2.7M | 3.1M | 3.5M | |
Inventory | 25.0M | 41.9M | 48.4M | 54.6M | 42.1M | 44.2M | |
Other Current Assets | 23.2M | 22.0M | 13.0M | 14.0M | 6.1M | 4.4M | |
Accounts Payable | 2.8M | 525K | 3.8M | 3.2M | 3.2M | 3.2M | |
Common Stock Total Equity | 782K | 903K | 913K | 1.0M | 1.2M | 658.0K | |
Common Stock | 903K | 913K | 1.0M | 1.2M | 1.5M | 1.6M | |
Other Assets | 346K | 16.6M | 17.7M | 15.7M | 18.1M | 19.0M | |
Short Term Investments | 319.1M | 103.4M | 67.0M | 69.5M | 51.7M | 55.8M | |
Property Plant Equipment | 19.6M | 22.7M | 33.6M | 29.8M | 34.3M | 36.0M | |
Net Tangible Assets | 403.8M | 236.5M | 77.6M | 13.6M | 15.6M | 14.8M | |
Retained Earnings Total Equity | (960.7M) | (1.2B) | (1.4B) | (1.6B) | (1.5B) | (1.4B) | |
Capital Surpluse | 1.3B | 1.6B | 1.6B | 1.7B | 1.9B | 2.0B | |
Short Long Term Debt | 28.7M | 4.6M | 5.6M | 7.1M | 8.1M | 8.3M | |
Net Invested Capital | 409.5M | 243.5M | 226.7M | 162.9M | 139.8M | 196.2M | |
Net Working Capital | 382.4M | 211.7M | 183.4M | 123.1M | 109.1M | 170.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Heron Therapeuti offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Heron Therapeuti's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Heron Therapeuti Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Heron Therapeuti Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Heron Stock analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Heron Therapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heron Therapeuti. If investors know Heron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heron Therapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Revenue Per Share 0.904 | Quarterly Revenue Growth 0.171 | Return On Assets (0.18) | Return On Equity (24.09) |
The market value of Heron Therapeuti is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeuti's value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeuti's market value can be influenced by many factors that don't directly affect Heron Therapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Heron Therapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heron Therapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.